Research Article

Target Groups for a Short Dexamethasone Course among Critically Ill COVID-19 Patients

Table 2

ICU management.

VariableDexamethasone (n = 83)Usual care (n = 137) value

Dexamethasone therapy
 Therapy start since the 1st day of fever, days, median (IQR)10 (8–13)NANA
 Duration of therapy, days, median (IQR)3 (3–3)
 Cumulative dose, mg, median (IQR)36 (28–40)
Hydroxychloroquine, n (%)19 (23)30 (22)0.864
Sarilumab, n (%)12 (14)8 (6)0.031
Tocilizumab, n (%)14 (17)13 (9)0.106
Antibiotics, n (%)81 (98)133 (97)0.822
DVT prophylaxis, n (%)83 (100)132 (96)0.078
RBC transfusion, n (%)21 (25)27 (20)0.330
Dialysis, n (%)24 (29)27 (20)0.117
Vasopressor agents, n (%)54 (65)66 (48)0.015
 NEpi, n (%)34 (41)41 (30)0.469
 NEpi + Epi, n (%)18 (22)22 (16)
 NEpi + Epi + other agents, n (%)2 (2)3 (2)
 Highest dose, mcg/kg, median (IQR)0.7 (0.2–1.2)0.6 (0.2–1.0)0.339
Nutrition, n (%)
 Oral intake20 (24)60 (44)0.003
 NG feeding tube50 (60)71 (52)0.224
 NG feeding tube + PN13 (16)6 (4)0.004
O2 therapy, n (%)
 Nasal cannula54 (65)102 (74)0.137
 HFNC14 (17)25 (18)0.867
 Noninvasive mechanical ventilation13 (16)3 (2)<0.001
Intubation, n (%)59 (71)71 (52)0.005
Tracheostomy, n (%)46/59 (78)40/71 (56)0.009
Day of tracheostomy after intubation, days, median (IQR)5 (3–7)6 (3–14)0.563
ECMO, n (%)1 (1.2)2 (1.5)0.865
Extubation/decannulation, n (%)27/59 (46)23/71 (32)0.119
Duration of ventilation, days, median (IQR)16 (9–22)12 (5–19)0.026
Duration of ventilation in survivors, days, median (IQR)20 (12–31)17 (12–25)0.158

CPAP, continuous positive airway pressure; DVT, deep vein thrombosis; ECMO, extracorporeal membrane oxygenation; Epi, epinephrine; HFNC, high-flow nasal cannula; ICU, intensive care unit; IQR, interquartile range; NA, not applicable; NEpi, norepinephrine; NG, nasogastric; PN, parenteral nutrition; RBC, red blood cells. Bold values denote statistical significance.